Thursday, February 11, 2016 5:50:02 PM
CytoSorb - Polymer-based system for adsorbing cytokines
Column CytoSorb
Attention! The system is a consumable item for single use only!
CytoSorb system - nonpyrogenic sterile biocompatible system for a single application designed for the removal of cytokines from the patient's blood by adsorption of using polymeric adsorbent peas contained within the system. A container with an adsorbent CytoSorb secured in a holder on the bar or IV pole, then use CytoSorb adapters connected to the extracorporeal circuit (mains) Blood Pump. The system works with any commercially available blood pump capable of providing flow rates up to 400 mL / min: it can be heart-lung machine, the machine of extracorporeal membrane oxygenation, apparatus for continuous renal replacement therapy, hemodialysis machine. Indications for use CytoSorb system: CytoSorb shows for use in cases of "cytokine storm", ie uncontrolled and not carrying the protective function of the activation of immune cells by cytokines in inflammation and the release of the latest new portion of cytokines due to the direct link between these processes. This occurs in the following cases: sepsis of any etiology; acute respiratory distress syndrome; during operations in cardiovascular and thoracic surgery; in septic patients with gipervospaleniem; in patients after surgery with severe sepsis and acute kidney damage beginning; in patients with acute concomitant diseases and sepsis (a weakened immune system), patients on chronic dialysis; in patients with chronic liver disease. The principle of operation CytoSorb system: Whole blood of the patient, anticoagulated with heparin or citrate throughput CytoSorb, mounted in a holder and connected via adapters in the standard line the blood pump (pump must be able to provide blood flow to 400 ml / min and have a pressure sensor in the lines). Inside CytoSorb occurs hydrophobic interactions (the molecules are drawn into the pores of the material selectively substances with a high concentration of adsorbed more strongly than the substance with a low concentration) spanning proteins average molecular weight, such as cytokines, peas adsorbent into the pores, depending on their concentration in the blood. Adsorbed CytoSorb cytokines remain in the system. More blood on highways perfusion pump returned to the patient. The pore size of the adsorbent within the peas systems allow particles to adsorb a molecular weight of about 8 to 55 kDa. Thus albumin and other proteins of high molecular weight remain in the patient's blood while other sorbents absorb and albumin. The adsorption particles CytoSorb system: The following is a graph illustrating various kinds of cytokines, which are subjected to adsorption using CytoSorb system indicating their sizes . Blue parabola CytoSorb designates the action system. Comments to the scheme: the white color on the chart denote proinflammatory cytokines yellow -protivovospalitelnye cytokines (IL-1ra, IL-13, IL-10, IL-4, TGF- ß), and soluble receptor sTNFR tumor necrosis factor, which is anti-inflammatory mediator. The height of the vertical columns scheme bears no semantic load. Other molecules whose concentration is reduced by CytoSorb: - myoglobin (molecular weight of 17 kDa) . - Bilirubin (MW 8 kD) CytoSorb on blood electrolyte balance is not affected. (D. Shedler et al. Journal of Critical Care 2013, 17 (Supplement 2): P.62 / D Schädler, et al; Critical Care 2013, 17 (Suppl 2):. P62) albumin minialny losses and account for less than 5% (D. Shedler etc. Magazine. critical Care 2013, 17 (Supplement 2): P.62 / D Schädler, et al; critical Care 2013, 17 (Suppl 2):. P62) The levels of C3a and C5b-9 (important quickly produced after the activation of the complement system proteins) in plasma are not rising, that is the use of CytoSorb does not trigger an immune cascade. An additional, apart from the standard, the level of monitoring of the concentration of cytokines during the use of the System is not required.
http://www.intensivmed.ru/index.php?option=com_content&view=category&layout=blog&id=42&Itemid=130&lang=ru
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM